Market Cap (In GBp)
16.54 Million
Revenue (In GBp)
1.15 Million
Net Income (In GBp)
4.1 Million
Avg. Volume
104.18 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 9.35-31.0
- PE
- -
- EPS
- -
- Beta Value
- 1.264
- ISIN
- GB00BYQ94H38
- CUSIP
- G6750T108
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Martin John Gouldstone
- Employee Count
- -
- Website
- https://www.oncimmune.com
- Ipo Date
- 2016-05-18
- Details
- Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
More Stocks
-
YHGJ
-
VWAPYVolkswagen AG
VWAPY
-
0DLIAcomo N.V.
0DLI
-
267260
-
SBKO
-
AVEAVE S.A.
AVE
-
OML
-
OLP